Radhakrishnan J, Halevy D
Columbia University College of Physicians & Surgeons, PH4124, 622 West 168th Street, NY 10032, USA.
Expert Opin Investig Drugs. 2000 May;9(5):1053-63. doi: 10.1517/13543784.9.5.1053.
Cyclosporin is a potent immunosuppressive agent that has become the first line therapy in organ transplantation. Its efficacy has led to its use in a variety of immune-mediated glomerular diseases. A selection of controlled and uncontrolled trials has studied the effects of cyclosporin in patients with minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), membranous nephropathy (MN), IgA nephropathy, membranoproliferative glomerulonephritis (MPGN) and lupus nephritis. We review the recent literature and suggest recommendations for using cyclosporin in these diseases, based on this evidence and our experience.
环孢素是一种强效免疫抑制剂，已成为器官移植的一线治疗药物。其疗效使其被用于多种免疫介导的肾小球疾病。一系列对照和非对照试验研究了环孢素对微小病变肾病（MCD）、局灶节段性肾小球硬化（FSGS）、膜性肾病（MN）、IgA肾病、膜增生性肾小球肾炎（MPGN）和狼疮性肾炎患者的影响。我们回顾了近期文献，并根据这些证据和我们的经验，提出在这些疾病中使用环孢素的建议。
